Abstract BACKGROUND Standard treatment with neoadjuvant nivolumab plus chemotherapy significantly improves outcomes in patients with resectable non–small-cell lung cancer (NSCLC). Perioperative treatment (i.e., neoadjuvant therapy
Editor’s summary Tumors, especially those with a high mutational burden, express neoantigens that may be recognized by an individual’s T cells. However, identifying and validating
Abstract Immune checkpoint blockade (ICB) targeting programmed cell death protein 1 (PD-1) and cytotoxic T lymphocyte protein 4 (CTLA-4) can induce remarkable, yet unpredictable, responses
Patients with an inherited form of colon cancer harbor two bacterial species that collaborate to encourage development of the disease, and the same species have
Created by ePubSystems. Contact Us for similar site for your university or institute.